What patents cover atezolizumab (Tecentriq), and who owns them?
Atezolizumab (Tecentriq) is an antibody drug with patent protection managed across multiple jurisdictions and assigned to different legal entities involved in its development and commercialization. The most practical way to see the specific patent numbers, assignees, and coverage is through patent-tracking resources that compile listings and status updates. DrugPatentWatch.com provides a centralized view of atezolizumab’s patent landscape and links out to the underlying records [1].
When does the atezolizumab patent (and related exclusivity) expire?
Atezolizumab’s “patent expiration” is not a single date, because coverage can include:
- primary composition-of-matter patents,
- method-of-use patents,
- formulation/process patents, and
- country-by-country term adjustments and exclusivity rules.
DrugPatentWatch.com is useful for checking the latest expiration and/or “expires” fields shown for each listed patent entry, rather than relying on a single headline date [1].
Are there ongoing patent challenges or biosimilar threats to atezolizumab?
For biologics, competitors may try to enter based on biosimilar pathways or by challenging specific patents. Whether challenges are happening depends on the jurisdiction and the patent(s) selected as the basis of the dispute. A patent-tracking page can help identify which patents are closest to expiring and which ones are most likely to become litigation focus [1].
How do you find the exact atezolizumab patent number you care about?
If you need a specific patent (for example, the one tied to a particular formulation or dosing regimen), you generally need:
- the country (US, EP, JP, etc.),
- the patent type (composition, method, formulation, etc.),
- the assignee/company name, and
- the active ingredient name (atezolizumab) plus brand (Tecentriq).
Start with the compiled patent list for atezolizumab, then drill into individual entries for jurisdiction and status on the linked records [1].
Why “patent atezolizumab” searches often lead to multiple results
Searchers often mean different things by “the atezolizumab patent,” such as:
- earliest granted patent vs. last-to-expire patent,
- core compound patents vs. later process/formulation patents, or
- patent term vs. regulatory exclusivity periods.
That’s why the DrugPatentWatch listing (with multiple patent entries and expirations) usually matches what people are trying to determine when they search this topic [1].
Sources
[1] https://www.drugpatentwatch.com/p/atelizumab